¹Section Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO, USA

Correspondence: AB Barqawi, MD, Section Urologic Oncology, University of Colorado Health Sciences Center, 6554 N Ursula Street, Suite 1004, PO Box 6510, Mail Stop F-710, Aurora, CO 80010, USA. E-mail: al.barqawi@uchsc.edu

Received 3 February 2005; Revised 3 February 2005; Accepted 2 March 2005; Published online 12 May 2005.

Abstract

Editor's note: The topic of testosterone (T) and prostate cancer is timely and provocative. The Institute of Medicine report on testosterone and aging suggested that knowledge regarding T-replacement therapy in aging men was inadequate, urging a cautious approach to T replacement in this population. The Food and Drug Administration appears to support this cautionary stance. Counter arguments by Rhoden and Morgentaler in the New England Journal of Medicine suggest that T-replacement therapy in aging men may be safe under controlled settings. This perspective continues the debate, and offers a unique perspective from the vantage point of a uro-oncologist.